Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313125922> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2313125922 abstract "ABSTRACT Aim: Retrospective analyses of clinical studies of pazopanib showed an increased median PFS in patients with plasma trough levels (TLs) ≥ 20.6 mg/L compared to patients with lower TLs (49.4 wks vs. 20.3 wks). This is in line with preclinical data showing optimal efficacy at concentrations above 17.5 mg/L. Due to inter-individual variability in plasma exposure, target TLs are not reached in ∼30% of patients with the current dosing schedule of 800 mg daily. Therefore, a Phase I study was performed to determine the safety and feasibility of pharmacokinetically (PK)-guided dosing of pazopanib. Methods: 30 patients with solid tumors with a potential benefit from pazopanib treatment were included. Weekly TLs were measured by LC-MS/MS. At week 3, 5 and 7 the dose could be increased when the measured TL was Results: At data cut-off (April 2014) the planned total of 30 patients was included of which 26 patients had completed the PK evaluation period of 8 weeks or had stopped treatment due to toxicity (n = 4). 14 out of 26 patients had at least one TL below the target during this period. Of these, 8 patients had successful dose increases of 25% to 125% (1,000 to 1,800 mg), without non-tolerable toxicity. The mean TL (CV%, range) increased from 12.3(41.9, 7.80 – 22.5) to 22.4 (44.0, 8.77 – 43.1) mg/L. In the remaining 6 patients dose escalation was not possible due to toxicity. 12 out of 26 patients had all TLs above target. Of these 12 patients, 8 patients needed a dose reduction due to grade 3 and 4 toxicity and, therefore, the mean TL in this group decreased from 49.1 (39.9, 30.2 – 79.5) to 26.3 (27.5, 17.8 – 36.0) mg/L. Conclusions: Individualized pharmacokinetically guided dosing of pazopanib is feasible and safe and leads to a higher proportion of patient reaching the desired target exposure. Additional (randomized) clinical trials on outcome parameters such as response rate and progression free survival are needed. Disclosure: All authors have declared no conflicts of interest." @default.
- W2313125922 created "2016-06-24" @default.
- W2313125922 creator A5000418012 @default.
- W2313125922 creator A5025499001 @default.
- W2313125922 creator A5027989286 @default.
- W2313125922 creator A5035333937 @default.
- W2313125922 creator A5038707468 @default.
- W2313125922 creator A5046734715 @default.
- W2313125922 creator A5050202217 @default.
- W2313125922 creator A5051744290 @default.
- W2313125922 creator A5062227574 @default.
- W2313125922 creator A5074174053 @default.
- W2313125922 creator A5078332643 @default.
- W2313125922 date "2014-09-01" @default.
- W2313125922 modified "2023-10-03" @default.
- W2313125922 title "Individualized Pharmacokinetically-Guided Dosing of Pazopanib: a Feasibility Study in Cancer Patients" @default.
- W2313125922 doi "https://doi.org/10.1093/annonc/mdu331.46" @default.
- W2313125922 hasPublicationYear "2014" @default.
- W2313125922 type Work @default.
- W2313125922 sameAs 2313125922 @default.
- W2313125922 citedByCount "1" @default.
- W2313125922 countsByYear W23131259222016 @default.
- W2313125922 crossrefType "journal-article" @default.
- W2313125922 hasAuthorship W2313125922A5000418012 @default.
- W2313125922 hasAuthorship W2313125922A5025499001 @default.
- W2313125922 hasAuthorship W2313125922A5027989286 @default.
- W2313125922 hasAuthorship W2313125922A5035333937 @default.
- W2313125922 hasAuthorship W2313125922A5038707468 @default.
- W2313125922 hasAuthorship W2313125922A5046734715 @default.
- W2313125922 hasAuthorship W2313125922A5050202217 @default.
- W2313125922 hasAuthorship W2313125922A5051744290 @default.
- W2313125922 hasAuthorship W2313125922A5062227574 @default.
- W2313125922 hasAuthorship W2313125922A5074174053 @default.
- W2313125922 hasAuthorship W2313125922A5078332643 @default.
- W2313125922 hasBestOaLocation W23131259221 @default.
- W2313125922 hasConcept C112705442 @default.
- W2313125922 hasConcept C121608353 @default.
- W2313125922 hasConcept C126322002 @default.
- W2313125922 hasConcept C126894567 @default.
- W2313125922 hasConcept C2777288759 @default.
- W2313125922 hasConcept C2778439243 @default.
- W2313125922 hasConcept C2779490328 @default.
- W2313125922 hasConcept C29730261 @default.
- W2313125922 hasConcept C71924100 @default.
- W2313125922 hasConcept C98274493 @default.
- W2313125922 hasConceptScore W2313125922C112705442 @default.
- W2313125922 hasConceptScore W2313125922C121608353 @default.
- W2313125922 hasConceptScore W2313125922C126322002 @default.
- W2313125922 hasConceptScore W2313125922C126894567 @default.
- W2313125922 hasConceptScore W2313125922C2777288759 @default.
- W2313125922 hasConceptScore W2313125922C2778439243 @default.
- W2313125922 hasConceptScore W2313125922C2779490328 @default.
- W2313125922 hasConceptScore W2313125922C29730261 @default.
- W2313125922 hasConceptScore W2313125922C71924100 @default.
- W2313125922 hasConceptScore W2313125922C98274493 @default.
- W2313125922 hasLocation W23131259221 @default.
- W2313125922 hasOpenAccess W2313125922 @default.
- W2313125922 hasPrimaryLocation W23131259221 @default.
- W2313125922 hasRelatedWork W2023956360 @default.
- W2313125922 hasRelatedWork W2049078873 @default.
- W2313125922 hasRelatedWork W2161576352 @default.
- W2313125922 hasRelatedWork W2382255163 @default.
- W2313125922 hasRelatedWork W2469879407 @default.
- W2313125922 hasRelatedWork W2500897030 @default.
- W2313125922 hasRelatedWork W2527810245 @default.
- W2313125922 hasRelatedWork W2598038721 @default.
- W2313125922 hasRelatedWork W2892616795 @default.
- W2313125922 hasRelatedWork W2944789678 @default.
- W2313125922 hasRelatedWork W2981596650 @default.
- W2313125922 hasRelatedWork W2982276445 @default.
- W2313125922 hasRelatedWork W2992991142 @default.
- W2313125922 hasRelatedWork W2994990079 @default.
- W2313125922 hasRelatedWork W3007672272 @default.
- W2313125922 hasRelatedWork W3011688938 @default.
- W2313125922 hasRelatedWork W3019726983 @default.
- W2313125922 hasRelatedWork W3135313725 @default.
- W2313125922 hasRelatedWork W3138230926 @default.
- W2313125922 hasRelatedWork W3154567952 @default.
- W2313125922 isParatext "false" @default.
- W2313125922 isRetracted "false" @default.
- W2313125922 magId "2313125922" @default.
- W2313125922 workType "article" @default.